In a regulatory filing, Maravai Lifesciences (MRVI) disclosed that its director Gregory Lucier bought 100K shares of common stock on December 5th as part of option exercise. Shares are up 9% afterhours at $4.01.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Closing Bell Movers: Inotiv surges after quarterly results
- Maravai Lifesciences CEO buys $702.7K of class A shares
- Maravai LifeSciences Earnings Call: Mixed Signals
- Maravai Lifesciences price target lowered to $4 from $5 at Stifel
- Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts